title: Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment.
abstract: The aim of our study was to measure serum concentrations of fibroblast growth factor 19 (FGF-19) in patients with obesity (OB), obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C) at baseline and after selected interventions. We measured serum FGF-19 levels and other biochemical and hormonal parameters in 29 OB and 19 T2DM females and 30 sex- and age-matched control subjects. The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp (n=11 for T2DM and 10 for C), very-low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-alpha agonist fenofibrate (n=11 for T2DM). Baseline serum FGF-19 levels were significantly lower in OB relative to C group (132.1+/-12.7 vs. 202.2+/-16.7 pg/ml, p<0.05), while no significant difference was observed between T2DM and OB or control group. Acute hyperinsulinemia tended to decrease FGF-19 levels in both healthy and T2DM subjects. Three weeks of VLCD in OB group had no significant effect on FGF-19, whereas three months of fenofibrate treatment markedly reduced FGF-19 levels in T2DM patients (194.58+/-26.2 vs. 107.47+/-25.0 pg/ml, p<0.05). We conclude that FGF-19 levels in our study were at least partially dependent upon nutritional status, but were not related to parameters of glucose metabolism or insulin sensitivity.
authors.affiliation: Third Department of Medicine, General University Hospital and First Medical Faculty, Charles University, Prague, Czech Republic.
authors.forename: M
authors.initials: M
authors.lastname: Mráz
authors.forename: Z
authors.initials: Z
authors.lastname: Lacinová
authors.forename: P
authors.initials: P
authors.lastname: Kaválková
authors.forename: D
authors.initials: D
authors.lastname: Haluzíková
authors.forename: P
authors.initials: P
authors.lastname: Trachta
authors.forename: J
authors.initials: J
authors.lastname: Drápalová
authors.forename: V
authors.initials: V
authors.lastname: Hanušová
authors.forename: M
authors.initials: M
authors.lastname: Haluzík
mesh_terms: D000208:Acute Disease; D000328:Adult; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D031204:Caloric Restriction / Q000379:methods; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000628:therapy; D005260:Female; D011345:Fenofibrate / Q000494:pharmacology / Q000627:therapeutic use; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood* / Q000628:therapy; D007333:Insulin Resistance; D008875:Middle Aged; D009765:Obesity / Q000097:blood*; D047493:PPAR alpha / Q000819:agonists* / Q000502:physiology*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; C117476:FGF19 protein, human; D047493:PPAR alpha; D005346:Fibroblast Growth Factors; D011345:Fenofibrate